INTRODUCTION
Metastatic non-small-cell lung cancer (NSCLC) is rarely curable and, despite significant treatment advances over the last decade, 5-year survival rates remain below 5%.
1 Current therapeutic options include histology-based chemotherapy, antiangiogenic agents, and targeted agents inhibiting epidermal growth factor receptor and anaplastic lymphoma kinase. Insulin-like growth factor 1 (IGF-1) receptor (IGF-1R) is a central component of cancer signal transduction pathways. 2 Expression of IGF-1R is detectable in 39% to 84% of advanced NSCLCs and is more frequently found in squamous cell lung cancer. 3 The prognostic significance of IGF-1R expression remains unclear. Several prospective studies suggest a relationship between circulating IGF-1 and cancer risk. 4, 5 Figitumumab (CP-751,871) is a fully human immunoglobulin G2 monoclonal antibody that inhibits IGF-1R. In phase I trials, it was well tolerated as a single agent and in combination with chemotherapy at 20 mg/kg every 3 weeks. 6, 7 In a randomized phase II study of patients with treatment-naive advanced NSCLC, the originally reported objective response rate (ORR) was 54% with figitumumab 10 or 20 mg/kg plus full-dose paclitaxel and carboplatin, and 42% with chemotherapy alone. Median
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progression-free survival (PFS) was initially reported as 5.0 months with figitumumab 20 mg/kg and 3.5 months with chemotherapy alone. No unexpected toxicities were observed. These findings prompted a prospective, randomized phase III trial of figitumumab plus paclitaxel and carboplatin compared with chemotherapy alone as first-line treatment for advanced NSCLC. However, the phase II data were subsequently retracted after a reanalysis revealed a lower ORR in both treatment arms (see Discussion). 8 In this article, we report the results of the phase III trial, which was restricted to patients with nonadenocarcinoma histology based on an initial analysis of the phase II study that indicated potentially increased figitumumab efficacy in this subset.
8

PATIENTS AND METHODS
Patients
Eligible patients were at least 18 years old with histologically or cytologically confirmed advanced NSCLC; documented American Joint Committee on Cancer 9 stage IIIB or metastatic (stage IV or recurrent) disease not amenable to curative treatment; and a primary histology of predominantly squamous cell, large cell, or adenosquamous carcinoma. Prior systemic treatment for NSCLC and previous or concurrent therapy with IGF-1R inhibitors or growth hormone agonists or antagonists were prohibited. Adjuvant chemotherapy was permitted if completed at least 12 months before randomization. Prior surgery or radiation therapy was permitted if completed at least 3 weeks before randomization, with all acute toxicities resolved to National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0 grade 1. Patients had to have an Eastern Cooperative Oncology Group performance status of 0 or 1 and adequate organ function. Exclusions included symptomatic CNS metastases, other active malignancies, uncontrolled hypertension, or uncontrolled diabetes (baseline glycosylated hemoglobin [HbA1 c ] Ͼ 8%).
The study was conducted in accordance with International Conference on Harmonisation Good Clinical Practice guidelines, the declaration of Helsinki, and local regulatory requirements and laws. Institutional review board or independent ethics committee approval was required for each investigator and center. Written informed consent was obtained from all patients.
Study Design and Treatment
Patients were randomly assigned in a 1:1 ratio to open-label figitumumab plus paclitaxel and carboplatin (investigational arm) or paclitaxel and carboplatin alone (control arm), stratified by previous adjuvant chemotherapy, sex, and histology (squamous-cell v combined large-cell or adenosquamous cancer).
The primary end point was overall survival (OS), which was defined as time from randomization to death as a result of any cause. Secondary end points included PFS, ORR, and safety. The association between serum IGF-1 levels and OS was a preplanned exploratory objective.
All patients received carboplatin (area under the concentration-time curve, 6 mg ⅐ min/mL) and paclitaxel (200 mg/m 2 ) intravenously on day 1 once every 3 weeks for up to six cycles. In the investigational arm, patients also received figitumumab 20 mg/kg intravenously on day 1 of each 3-week cycle, for up to 17 cycles (approximately 1 year of treatment).
On the investigational arm, if paclitaxel and/or carboplatin were discontinued early, patients could continue single-agent figitumumab (once every 3 weeks) until disease progression or intolerance. Additional cycles were permitted in patients exhibiting response, based on agreement between the study sponsor and investigator. If figitumumab was discontinued, paclitaxel and carboplatin were continued for a maximum of six cycles until disease progression or intolerance. Standard supportive therapies were instituted in both arms. Guidelines for managing emergent hyperglycemia were provided, including immediate treatment, protocol-defined figitumumab-dosage modification, and continued oral glucose-lowering therapy if hyperglycemia was expected to continue.
Study Procedures
Tumor assessment was performed at baseline and every 6 weeks until radiologic disease progression or initiation of subsequent anticancer therapy using Response Evaluation Criteria in Solid Tumors version 1.0.
10 Adverse events were graded using National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0. Clinical assessments, including hematology and serum chemistry, were performed at baseline, on day 1 of cycle 1 (all measurements), days 8 and 15 of cycle 1 (hematology only), on day 1 of each subsequent cycle, and at the end of treatment. Levels of HbA1 c were measured at baseline, before cycle 4, and at the end of treatment.
Serum samples were collected within 2 hours before chemotherapy and/or figitumumab infusion at cycles 1 and 4 and at the end of treatment. Total IGF-1 levels were determined by immunochemiluminometric assay at MDS Pharma Services (now LabCorp; Mississauga, Ontario, Canada). An independent Data Safety Monitoring Committee (DSMC) monitored safety and efficacy.
Statistical Analysis
With one-sided .025 level testing and 90% power, 820 patients were needed to detect a 30% improvement for figitumumab plus chemotherapy over the median 10-month survival rate seen with paclitaxel plus carboplatin therapy (hazard ratio [HR], 0.77); 649 events were expected at full follow-up. The primary assessment was a log-rank test stratified by factors used in randomization. The analysis set included all randomly assigned patients on an intent-to-treat basis. Two-sided P values were determined.
Two interim analyses were planned after approximately one third and two thirds of the anticipated number of events had occurred. A Lan-DeMets spending function approach with O'Brien-Fleming stopping bounds (Appendix Table A1 [online-only]) was used to reject the null hypothesis (efficacy boundary) and the alternative hypothesis (futility boundary). Statistical analyses were conducted by Pfizer.
RESULTS
Patients and Treatment Exposure
Between April 2008 and September 2009, 681 patients from 163 sites in 25 countries were randomly assigned and 671 received treatment (figitumumab group, 338; control group, 333; Fig 1) . Demographic and baseline characteristics were well balanced between treatment arms (Table 1) . Patients' median age was 62 years. Most of the patients were men and most had stage IV disease. Patients in the figitumumab and control arms received a median of four and five cycles of chemotherapy, respectively (Table 2) ; 33% and 44%, respectively, completed six cycles of paclitaxel, and 34% and 46% completed six cycles of carboplatin. Figitumumab-treated patients received a median of four figitumumab cycles; 109 (32%) of 338 figitumumabtreated patients received four to six cycles, seven (2%) of 338 patients received 17 cycles, and four (1%) of 338 received more than 20 cycles. A total of 124 (37%) of 338 patients received figitumumab after completing or discontinuing chemotherapy (median of two maintenance cycles). Of these, 87 (26%) of 338 patients received figitumumab maintenance after six cycles (maintenance therapy could start earlier than cycle 6).
On DSMC advice, enrollment was suspended in September 2009 because of a higher number of serious adverse events (SAEs) and deaths in the figitumumab arm. The study was permanently closed to new accrual in December 2009, after the first interim analysis indicated that the addition of figitumumab was highly unlikely to meet the primary end point of improving OS over chemotherapy alone. Follow-up for OS continued until March 2011. The overall median follow-up time was 23.1 months (Table 3) .
Efficacy
At the final analysis, 259 patients in the figitumumab arm and 251 in the control arm had died (Table 3 ). The median OS was 8.6 months (95% CI, 7.4 to 9.3) and 9.8 months (95% CI, 8.6 to 10.9), respectively (HR, 1.18; 95% CI, 0.99 to 1.40; P ϭ .06; Fig 2A) . Respective 1-year survival rates were 34% and 39%. The effect of figitumumab was similar across all subgroups based on demographic or other baseline characteristics (Fig 3) .
Median PFS was 4.7 months for the figitumumab arm (95% CI, 4.2 to 5.4) and 4.6 months for the control arm (95% CI, 4.2 to 5.4; HR, 1.10; 95% CI, 0.93 to 1.32; P ϭ .27; Fig 2B) . Respective ORRs were 33% (95% CI, 28 to 38) and 35% (95% CI, 29 to 40; Table 3 ).
Safety
Alopecia and nausea were the most common treatmentemergent (all-causality) adverse events (AEs) of any grade and occurred in a similar number of patients in each arm (Table 4) .
Any-grade AEs that occurred more frequently in the figitumumab arm included hyperglycemia, diarrhea, decreased appetite, vomiting, and decreased weight. Grade 3/4 AEs that occurred more frequently in the figitumumab arm included hyperglycemia, decreased appetite, dehydration, diarrhea, fatigue, and nausea.
Treatment-emergent (all-causality) SAEs occurred in 66% of the figitumumab arm and 51% of the control arm (P Ͻ .01 by Fisher's exact test). Excluding disease progression, the most common SAEs were pneumonia (6% v 4%, respectively), dehydration (4% v 1%), asthenia (3% v 1%), and hyperglycemia (3% v Ͻ 1%). The SAEs were judged to have a reasonable possibility of being treatment-related in 22% and 12% of patients, respectively.
Nonprogression grade 5 AEs occurred in 13% of the figitumumab arm and 10% of the control arm (P ϭ .22). The most common grade 5 AEs in the figitumumab arm were pulmonary hemorrhage and pneumonia (2% each; Appendix Table A2 ). Grade 5 AEs were considered to be treatment-related in 5% of the 
Receiving figitumumab at time of data cutoff (n = 2) Receiving chemotherapy at time of data cutoff (n = 0) ) figitumumab arm and 1% of the control arm (P Ͻ .01). With figitumumab, these grade 5 AEs included hemoptysis, pneumonia, unknown cause reported only as death, septic shock, cardiorespiratory arrest, decrease of performance status, neutropenic sepsis, toxicity to various agents, renal failure, hemorrhage, and hypovolemic shock (Յ 1% each). In the control arm, the grade 5 AEs included unknown cause reported as death, pneumonia, septic shock, and dehydration (Ͻ 1% each).
Figitumumab was discontinued because of treatment-related AEs in 7% of patients, and chemotherapy was discontinued for this reason in 9% of patients in each arm.
Relationship of Total IGF-1 and HbA1 c to Outcomes
For the exploratory analysis of outcomes based on baseline total IGF-1, a cutoff of 120 ng/mL was selected because it was associated with the largest observed differences in treatment effect above and below it. Baseline IGF-1 was not related to overall frequency or nature of AEs. However, grade 5 AEs were more common among figitumumab-treated patients with baseline IGF-1 levels less than 120 ng/mL (56%) than among those with baseline levels of 120 ng/mL or higher (38%) and those in the control arm (37% and 36% in the low and high IGF-1 groups, respectively). In the figitumumab arm, median OS for patients with low and high baseline IGF-1 was 7.0 months and 10.4 months, respectively; in the control arm it was 10.1 and 9.4 months, respectively (Appendix Fig A1) . For patients with high IGF-1, there was no difference in OS between treatment groups (HR, 0.93; P ϭ .67). For those patients with low IGF-1, OS was significantly shorter in the figitumumab arm (HR, 1.37; P ϭ .01).
The rate of all-causality AEs did not vary markedly by baseline HbA1 c status, but the rate of grade 3/4 AEs for patients with no grade 5 events was slightly lower in those with baseline levels less than 5.7% than in those with levels Ն 5.7% (figitumumab arm, 30% v 36%; control arm, 33% v 35%). Median OS in patients with low baseline HbA1 c was 8.7 months in the figitumumab arm and 10.2 months in the control arm (HR, 1.07; P ϭ .65). The respective values in patients with high HbA1 c were 8.2 and 9.7 months (HR, 1.26; P ϭ .05).
DISCUSSION
This was the first randomized phase III study to test whether combining an IGF-1R inhibitor (figitumumab) with paclitaxel and carboplatin could improve OS versus chemotherapy alone as first-line treatment for advanced nonadenocarcinoma NSCLC. When this trial was initiated, IGF-1R was thought to play an important role in squamous cell histology NSCLC, an area of particular unmet need. Unexpectedly, adding figitumumab to chemotherapy proved deleterious. The DSMC closed the study because of therapeutic futility and increased SAEs, including treatment-related deaths, in the figitumumab arm. This outcome was disappointing given the originally reported phase II ORR of 54% for combination therapy compared with 42% for chemotherapy alone. 8 The phase III study was designed and conducted in good faith based on the aforementioned phase II trial findings in treatment-naive advanced NSCLC. Following closure of the phase III trial, the phase II data were retracted after a reanalysis revealed a lower ORR in both treatment arms. 8 In addition, median PFS no longer trended in favor of figitumumab (4.5 months with figitumumab 20 mg/kg and 4.3 months with chemotherapy alone). The heightened toxicity of figitumumab in the phase III trial was not observed in the original phase I/II trials in NSCLC, which enrolled more than 150 patients in total. In our current study, the figitumumab combination failed to improve any efficacy end points over chemotherapy alone. Overall survival, the primary end point, was 8.6 months versus 9.8 months respectively. The ORR with figitumumab (33%) was similar to that observed in the phase II final analysis (37% in both the overall cohort [initially reported as 54%] and the nonadenocarcinoma cohort). Another advanced NSCLC trial, initiated after the phase III was underway, used the same treatment in combination with figitumumab and the ORR was 39%. 12 Subgroup analysis suggests that figitumumab safety and tolerability were poorer in patients with low baseline IGF-1 (Ͻ 120 ng/mL) compared with those with high IGF-1 (Ն 120 ng/mL), particularly NOTE. Data are presented for all patients by randomized arm. The stratification factors (histology, sex, and adjuvant chemotherapy) are presented as collected in the case report forms rather than as collected by the randomization system. Abbreviation: ECOG, Eastern Cooperative Oncology Group.
‫ء‬
TNM Classification of Malignant Tumours (6th ed).
11 †Systemic therapy included carboplatin/paclitaxel (n ϭ 3), cisplatin/vinorelbine (n ϭ 7), cisplatin/gemcitabine (n ϭ 4), carboplatin/gemcitabine (n ϭ 3), cisplatin/etoposide (n ϭ 3), other regimens with carboplatin (n ϭ 3), other regimens with cisplatin (n ϭ 4), and other nonplatinum regimens (n ϭ 2).
with respect to grade 5 AEs. Consequently, in the figitumumab arm, median OS was shorter in patients with low IGF-1 compared with those with high IGF-1 and was significantly shorter compared with control patients who had low IGF-1 (HR, 1.37, P ϭ .01). Although additional studies are required, these data suggest that low baseline total IGF-1 may be a safety biomarker that identifies a subset of patients for whom IGF-1R inhibition is particularly harmful. In a phase I study of ganitumab, a human monoclonal antibody against IGF-1R, treatment transiently increased IGF-1. 13 Low baseline IGF-1 may indicate an inability to mount a compensatory increase in IGF-1 and greater likelihood of AEs.
Hyperglycemia of any grade occurred more frequently in the figitumumab arm than in the control arm (23% v 5%), as did grade 3/4 hyperglycemia(12%v1%).Hyperglycemiawasoneofthemostcommon SAEs, with greater frequency in the figitumumab arm than in the control arm. Hyperglycemia is likely a class effect stemming from impaired homeostatic control of glucose metabolism as a consequence of IGF-1R inhibition.
14 Hyperglycemia was rarely severe and was usually manageable with agents such as metformin, but could have contributed in subtle ways to increased toxicity in the figitumumab arm.
Baseline HbA1 c was not a strong biosafety marker, although grade 3/4 AEs were slightly more common in patients with levels 
‫ء‬
Patients in the chemotherapy arm who received carboplatin, n ϭ 332. †Includes experience after data cutoff from the last ongoing patient, who transitioned to single patient IND in September 2012. 
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www.jco.org Ն 5.7% than in those with levels less than 5.7% in both treatment arms. Median OS was approximately 1.5 months shorter in the figitumumab arm than in the control arm, regardless of baseline HbA1 c (HR: patients with low HbA1 c , 1.07; patients with high levels, 1.26).
Beyond the failure to demonstrate efficacy, a worrisome finding of this study was the relatively high frequency of treatment-related deaths associated with figitumumab (5%), an effect that was not detected in the phase II study. There are a number of potential reasons that may provide insight for future clinical trial design, dosing levels, and anticipation and management of toxicities, particularly where combination regimens are involved. First, only about half of the 98 patients randomly assigned to figitumumab in the phase II trial received the 20 mg/kg dose, a sample that might have been too small to detect safety signals. However, the incidence of grade 3/4 hyperglycemia was greater in the phase II study (20%) than in our current study (12%).
8 Second, there were inherent differences in the patient populations. For example, the phase III study enrolled patients with predominantly squamous cell histology and far more current smokers (42% v 13%) than the phase II study. Hence, the phase III patient population may have had more attendant comorbidities (latent or overt), which might have rendered them more vulnerable to toxicity or intercurrent grade 5 events. Third, the phase II trial was conducted almost exclusively at tertiary referral centers, which may have led to subtle differences in the types of patients enrolled and how they were managed. As several study centers in the phase III trial enrolled only a few patients each, the investigators may have initially lacked Furthermore, although patient and disease characteristics were well balanced between arms, we cannot exclude the possibility that minor baseline demographic imbalances in this study might have produced inconsistent results. Although figitumumab was combined with the same full-dose chemotherapy doublet as in the phase II study, lower doses of the doublet might have improved the tolerability of the combination. Finally, the difference in the incidence of treatmentrelated grade 5 AEs between the figitumumab and control arms (5% v 1%), may indicate that signaling through IGF-1R and its attendant pathways is critical in maintaining homeostasis, such that inhibition significantly disrupts the insulin receptor/IGF-1R/growth-hormone signaling axis. This concern may be heightened in patients with advanced squamous cell NSCLC, who often have multiple comorbidities and who constituted the vast majority of participants in this trial. Our experience highlights the potential discrepancies between phase II and phase III trials in both safety and efficacy, and underscores the importance of identifying a priori the patient population(s) most likely to benefit from therapy. However, as seen in our current study, inclusion of such a selected patient group (predominantly squamous cell NSCLC) does not guarantee improved safety or efficacy.
In conclusion, though the phase II trial suggested an ORR advantage for adding figitumumab to standard chemotherapy in advanced NSCLC, our current phase III study involving nonadenocarcinoma patients failed to show any benefit and unexpectedly suggested a possible detrimental effect. This may be a class effect and should be assessed in current and future trials examining IGF-1R inhibitors. Further clinical development of figitumumab is not being pursued. 
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